Prevalence and characteristics of the metabolic syndrome in Chinese hypertensive patients: A hospital-based observation

Acta Cardiologica Sinica

Volumn 21, Issue 2, 2005, Pages 89-97

  Hsu, Chih Neng ^a   Chen, Ya Chun ^b   Wang, Tzung Dau ^b  

^a MIN SHENG GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hypertension; Insulin resistance; Metabolic syndrome; Uric acid

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OBSERVATION; PREVALENCE; PROTEINURIA; SEX RATIO; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 26944433053     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421.
2. Jermendy G, Hetyési K, Bíró L, et al. Prevalence of the metabolic syndrome in hypertensive and/or obese subjects. Diabetic Medicine 2004;21:805-6.
3. Jia WP, Xiang KS, Chen L, et al. A comparison of the application of two working definitions of metabolic syndrome in Chinese population. Zhonghua Yi Xue Za Zhi 2004;84:534-8.
4. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6.
5. Jia WP, Xiang KS, Chen L, et al. Epidemiological study on obesity and its comorbidities in urban Chinese older than 20 years of age in Shanghai, China. Obes Rev 2002;3:157-65.
6. Chuang SY, Chen CH, Tsai ST, Chou P. Clinical identification of the metabolic syndrome in Kinmen. Acta Cardiol Sin 2002;18:16-23.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
8. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus; Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.
9. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004;64:2537-65.
10. Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996;9:150-4S.
11. Wang TD, Chen WJ, Lin JW, et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in non-diabetic patients with the metabolic syndrome. Am J Cardiol 2004;93:362-5.
12. Wang TD, Chen WJ, Chien KL, et al. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol 2001;88:737-43.
13. Abbasi AS, MacAlpin RN, Eber LM, Pearce ML. Left ventricular hypertrophy diagnosed by echocardiography. N Engl J Med 1973; 289:118-21.
14. Devereux RB, Reichek N. Echocardiography determination of left ventricular mass in man: anatomical validation of the method. Circulation 1977;55:613-8.
15. Devereux RB, Alonso D, Lutas E, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison of necropsy findings. Am J Cardiol 1986;57:450-8.
16. Solymoss BC, Bourassa MG, Lesperance J, et al. Incidence and characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis 2003;14:207-12.
17. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995;13:1457-62.
18. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004;93:159-64.
19. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-71.
20. Srinivas K, Bhaskar MV, Aruna Kumari R, et al. Antioxidants, lipid peroxidation and lipoproteins in primary hypertension. Indian Heart J 2000;52:285-8.
21. Flesch M, Sachinidis A, Ko YD, et al. Plasma lipids and lipoproteins and essential hypertension. Clin Invest 1994;72:944-50.
22. Catalano M, Aronica A, Carzaniga G, et al. Serum lipids and apolipoproteins in patients with essential hypertension. Atherosclerosis 1991;87:17-22.
23. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004;4:9.
24. Matsubara M, Chiba H, Maruoka S, Katayose S. Elevated serum leptin concentrations in women with hyperuricemia. J Atheroscler Thromb 2002;9:28-34.
25. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21:1563-74.
26. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-41.
27. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.